RNA interference targeting the R2 subunit of ribonucleotide reductase inhibits growth of tumor cells in vitro and in vivo

Anti-Cancer Drugs

Volumn 18, Issue 4, 2007, Pages 377-388

  Avolio, Tina M ^a   Lee, Yoon ^a   Feng, Ningping ^a   Xiong, Keyong ^a   Jin, Hongnan ^a   Wang, Ming ^a   Vassilakos, Aikaterini ^a   Wright, Jim ^a   Young, Aiping ^a  

^a Lorus Therapeutics Inc   (Canada)

Author keywords

Cancer; Ribonucleotide reductase; RNA interference; Short interfering RNA; Therapeutic; Xenograft

Indexed keywords

GEMCITABINE; SMALL INTERFERING RNA; RIBONUCLEOTIDE REDUCTASE; RIBONUCLEOTIDE REDUCTASE R2 SUBUNIT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE; COLON ADENOCARCINOMA; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; GENE SEQUENCE; GENE TARGETING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MELANOMA; METASTASIS; MOUSE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; RNA INTERFERENCE; WESTERN BLOTTING; XENOGRAFT; ANIMAL; BIOSYNTHESIS; CANCER TRANSPLANTATION; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL STRAIN HT29; DENSITOMETRY; DOSE RESPONSE; DRUG EFFECT; GENETICS; MOUSE MUTANT; NEOPLASM; TUMOR CELL LINE;

ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DENSITOMETRY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; HT29 CELLS; HUMANS; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASMS; RIBONUCLEOTIDE REDUCTASES; RNA, SMALL INTERFERING; S PHASE; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 34247567981     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328013c04f     Document Type: Article

References (85)

1. Cerutti H. RNA interference: traveling in the cell and gaining functions. Trends Genet 2003; 19:39-46.
2. Cogoni C, Macino G. Post-transcriptional gene silencing across kingdoms. Curr Opin Genet Dev 2000; 10:638-643.
3. Napoli C, Lemieux C, Jorgensen R. Introduction of a chimeric chalcone synthase gene into petunia results in reversible co-suppression of homologous genes in trans. Plant Cell 1990; 2:279-289.
4. Ketting RF, Haverkamp THA, van Luenen HGAM, Plasterk RHA. mut-7 of C. elegans, required for transposon silencing and RNA interference, is a homolog of Werner syndrome helicase and RNaseD. Cell 1999; 99:133-141.
5. Sijen T, Plasterk RHA. Transposon silencing in the Caenorhabditis elegans germ line by natural RNAi. Nature 2003; 426:310-314.
6. Vaucheret H, Béclin C, Fagard M. Post-transcriptional gene silencing in plants. J Cell Sci 2001; 114:3083-3091.
7. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391:806-811.
8. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001; 409:363-366.
9. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J 2001; 20:6877-6888.
10. Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 2000; 404:293-296.
11. Zamore PD, Tuschl T, Sharp PA, Bartel DP. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000; 101:25-33.
12. Hutvagner G. Small RNA asymmetry in RNAi: function in RISC assembly and gene regulation. FEBS Lett 2005; 579:5850-5857.
13. Schwarz DS, Hutvágner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003; 115:199-208.
14. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001; 15:188-200.
15. Hammond SM, Boettcher S, Caudy AA, Kobayashi R, Hannon GJ. Argonaute2, a link between genetic and biochemical analysis of RNAi. Science 2001; 293:1146-1150.
16. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomas JM, Song JJ, et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 2004; 305:1437-1441.
17. Martinez J, Patkaniowska A, Urlaub H, Lührmann R, Tuschl T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 2002; 110:563-574.
18. 2+-dependent endonuclease. Curr Biol 2004; 14:787-791.
19. Tuschl T, Zamore PD, Lehmann R, Bartel DP, Sharp PA. Targeted mRNA degradation by double-stranded RNA in vitro. Genes and Dev 1999; 13:3191-3197.
20. Harborth J, Elbashir SM, Bechert K, Tuschl T, Weber K. Identification of essential genes in cultured mammalian cells using small interfering RNAs. J Cell Sci 2001; 114:4557-4565.
21. Ito M, Kawano K, Miyagishi M, Taira K. Genome-wide application of RNAi to the discovery of potential drug targets. FEBS Lett 2005; 579:5988-5995.
22. Kittler R, Buchholz F. RNA interference: gene silencing in the fast lane. Semin Cancer Biol 2003; 13:259-265.
23. Semizarov D, Kroeger P, Fesik S. siRNA-mediated gene silencing: a global genome view. Nucleic Acids Res 2004; 32:3836-3845.
24. Dorn G, Patel S, Wotherspoon G, Hemmings-Mieszczak M, Barclay J, Natt FJC, et al. siRNA relieves chronic neuropathic pain. Nucleic Acids Res 2004; 32:e49.
25. Giladi H, Ketzinel-Gilad M, Rivkin L, Felig Y, Nussbaum O, Galun E. Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther 2003; 8:769-776.
26. Hoeflich KP, Gray DC, Eby MT, Tien JY, Wong L, Bower J, et al. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 2006; 66:999-1006.
27. McCaffrey AP, Nakai H, Pandey K, Huang Z, Salazar FH, Xu H, et al. Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 2003; 21:639-644.
28. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003; 9:347-351.
29. Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004; 64:3365-3370.
30. Pai S, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC. Prospects of RNA interference therapy for cancer. Gene Therapy 2006; 13:464-477.
31. Uprichard SL. The therapeutic potential of RNA interference. FEBS Lett 2005; 579:5996-6007.
32. Cory JG. Purine and pyrimidine nucleotide metabolism. In: Devlin T, editors. Biochemistry with clinical correlations. 4th ed. New York: Wiley-Liss; 1997. pp. 489-523.
33. Jordan A, Reichard P. Ribonucleotide reductases. Annu Rev Biochem 1998; 67:71-98.
34. Thelander L, Berg P. Isolation and characterization of expressible cDNA clones encoding the M1 and M2 subunits of mouse ribonucleotide reductase. Mol Cell Biol 1986; 6:3433-3442.
35. von Döbeln U, Reichard P. Binding of substrates to Escherichia coli ribonucleotide reductase. J Biol Chem 1976; 251:3616- 3622.
36. Engström Y, Eriksson S, Jildevik I, Skog S, Thelander L, Tribukait B. Cell cycle-dependent expression of mammalian ribonucleotide reductase. J Biol Chem 1985; 260:9114-9116.
37. Eriksson S, Gudas LJ, Clift SM, Caras IW, Ullman B, Martin DW. Evidence for genetically independent allosteric regulatory domains of the protein M1 subunit of mouse ribonucleotide reductase. J Biol Chem 1981; 256:10193-10197.
38. Mann GJ, Musgrove EA, Fox RM, Thelander L. Ribonucleotide reductase M1 subunit in cellular proliferation, quiescence and differentiation. Cancer Res 1988; 48:5151-5156.
39. Thelander L, Reichard P. Reduction of ribonucleotides. Annu Rev Biochem 1979; 48:133-158.
40. Larsson A, Sjöberg BM. Identification of the stable free radical tyrosine residue in ribonucleotide reductase. EMBO J 1986; 5:2037-2040.
41. Thelander M, Gräslund A, Thelander L. Subunit M2 of mammalian ribonucleotide reductase. J Biol Chem 1985; 260:2737-2741.
42. Eriksson S, Gräslund A, Skog S, Thelander L, Tribukait B. Cell cycle-dependent regulation of mammalian ribonucleotide reductase. J Biol Chem 1984; 259:11695-11700.
43. Eriksson S, Martin DW. Ribonucleotide reductase in cultured mouse lymphoma cells. J Biol Chem 1981; 256:9436-9440.
44. Nakano K, Bálint E, Ashcroft M, Vousden KH. A ribonucleotide reductase gene is a transcriptional target of p53 and p73. Oncogene 2000; 19:4283-4289.
45. Tanaka H, Arakawa H, Yamaguchi T, Shiraishi K, Fukuda S, Matsui K, et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. Nature 2000; 404:42-49.
46. Lozano G, Elledge SJ. p53 sends nucleotides to repair DNA. Nature 2000; 404:24-25.
47. Yamaguchi T, Matsuda K, Sagiya Y, Iwadate M, Fujino MA, Nakamura Y, et al. p53R2-dependent pathway for DNA synthesis in a p53-regulated cell cycle checkpoint. Cancer Res 2001; 61:8256-8262.
48. Guittet O, Håkansson P, Voevodskaya N, Fridd S, Gräslund A, Arakawa H, et al. Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J Biol Chem 2001; 276:40647-40651.
49. Elford HL, Freese M, Passamani E, Morris HP. Ribonucleotide reductase and cell proliferation. J Biol Chem 1970; 245:5228-5233.
50. Weber G. Biochemical strategy of cancer cells and the design of chemotherapy: GHA Clowes Memorial Lecture. Cancer Res 1983; 43:3466-3492.
51. Fan H, Villegas C, Huang A, Wright JA. The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. Cancer Res 1998; 58:1650-1653.
52. Fan H, Villegas C, Wright JA. Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential. Proc Natl Acad Sci U S A 1996; 93:14036-14040.
53. Zhou BS, Tsai P, Ker R, Tsai J, Ho R, Yu J, et al. Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential. Clin Exp Metastasis 1998; 16:43-49.
54. Kuo ML, Hwang HS, Sosnay PR, Kunugi KA, Kinsella TJ. Overexpression of the R2 subunit of ribonucleotide reductase in human nasopharyngeal cancer cells reduces radiosensitivity. Cancer J 2003; 9:277-285.
55. Huang A, Fan H, Taylor WR, Wright JA. Ribonucleotide reductase R2 gene expression and changes in drug sensitivity and genome stability. Cancer Res 1997; 57:4876-4881.
56. Zhou BS, Hsu NY, Pan BC, Doroshow JH, Yen Y. Overexpression of ribonucleotide reductase in transfected human KB cells increases their resistance to hydroxyurea: M2 but not M1 is sufficient to increase resistance to hydroxyurea in transfected cells. Cancer Res 1995; 55:1328-1333.
57. Goan YG, Zhou B, Hu E, Mi S, Yen Y. Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 1999; 59:4204-4207.
58. Jung CP, Motwani MV, Schwartz GK. Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin Cancer Res 2001; 7:2527-2536.
59. Choy BK, McClarty GA, Wright JA. Transient elevation of ribonucleotide reductase activity, M2 mRNA and M2 protein in BALB/c 3T3 fibroblasts in the presence of 12-O-tetradecanoylphorbol-13-acetate. Biochem Biophys Res Commun 1989; 162:1417-1424.
60. Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol 1992; 19:1-10.
61. Barker CA, Burgan WE, Carter DJ, Cerna D, Gius D, Hollingshead MG, et al. In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine-2- carboxaldehydethiosemicarbazone). Clin Cancer Res 2006; 12:2912-2918.
62. Yee KW, Cortes J, Ferrajoli A, Garcia-Manero G, Verstovsek S, Wierda W, et al. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leuk Res 2006; 30:813-822.
63. Rappa G, Lorico A, Liu MC, Kruh GD, Cory AH, Cory JG, et al. Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase. Biochem Pharmacol 1997; 54:649-655.
64. Duxbury MS, Ito H, Benoit E, Zinner MJ, Ashley SW, Whang EE. Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase: a novel therapeutic strategy in pancreatic cancer. Surgery 2004; 136:261-269.
65. Duxbury MS, Ito H, Zinner MJ, Ashley SW, Whang EE. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 2004; 23:1539-1548.
66. Lee Y, Vassilakos A, Feng N, Lam V, Xie H, Wang M, et al. GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. Cancer Res 2003; 63:2802-2811.
67. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001; 411:494-498.
68. Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 2002; 26:199-213.
69. McClarty GA, Chan AK, Engstrom Y, Wright JA, Thelander L. Elevated expression of M1 and M2 components and drug-induced posttranscriptional modulation of ribonucleotide reductase in a hydroxyurea-resistant mouse cell line. Biochemistry 1987; 26:8004-8011.
70. Wright JA, Alam TG, McClarty GA, Tagger AY, Thelander L. Altered expression of ribonucleotide reductase and role of M2 gene amplification in hydroxyurea-resistant hamster, mouse, rat, and human cell lines. Somat Cell Mol Genet 1987; 13:155-165.
71. Pavloff N, Rivard D, Masson S, Shen SH, Mes-Masson AM. Sequence analysis of the large and small subunits of human ribonucleotide reductase. DNA Seq 1992; 2:227-234.
72. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, et al. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003; 21:635-637.
73. Bridge AJ, Pebernard S, Ducraux A, Nicoulaz AL, Iggo R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat Genet 2003; 34:263-264.
74. Minks MA, West DK, Benvin S, Baglioni C. Structural requirements of double-stranded RNA for the activation of 2′,5′-oligo(A) polymerase and protein kinase of interferon-treated HeLa cells. J Biol Chem 1979; 254:10180-10183.
75. Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun 2002; 296:1000-1004.
76. Miyagishi M, Hayashi M, Taira K. Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammaliam cells. Antisense Nucleic Acid Drug Dev 2003; 13:1-7.
77. Cullen BR. Induction of stable RNA interference in mammalian cells. Gene Therapy 2006; 13:503-508.
78. Dorsett Y, Tuschl T. siRNAs: applications in functional genomics and potential as therapeutics. Nat Rev Drug Discov 2004; 3:318-329.
79. Dykxhoorn DM, Palliser D, Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Therapy 2006; 13:541-552.
80. Sioud M, Sørensen DR. Cationic liposome-mediated delivery of siRNAs in adult mice. Biochem Biophys Res Commun 2003; 312:1220-1225.
81. Sørensen DR, Leirdal M, Sioud M. Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol 2003; 327:761-766.
82. Xie FY, Woodle MC, Liu PY. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov Today 2006; 11:67-73.
83. Chiu YL, Rana TM. siRNA function in RNAi: a chemical modification analysis. RNA 2003; 9:1034-1048.
84. Czauderna F, Fechtner M, Dames S, Aygün H, Klippel A, Pronk GJ, et al. Structural variations and stabilizing modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 2003; 31:2705-2716.
85. Soutschek J, Akinc A, Bramlage B, Charisse K, Constein R, Donoghue M, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004; 432:173-178.